Soliton, Inc.,, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, announced that it will release the cumulative 26-week patient data from its cellulite proof of concept clinical trial on Monday, July 15, 2019.
July 8, 2019
· 4 min read